Institute for Bioscience and Biotechnology Research Receives $16.8 M Investment from the National Institute of Standards and Technology

Published on : January 17, 2022January 17, 2022 Published by : BioBuzz Media

The Institute for Bioscience and Biotechnology Research (IBBR) announces a newly funded five-year cooperative agreement with the National Institute of Standards and Technology (NIST) headed by the Co-Directors of IBBR, Dr. David J. Weber (PI) and Dr. John Marino (NIST). This award provides more than $3.3 million each year to support groundbreaking research, including technology and standards development that will impact vaccine and therapeutic discovery and development, and to improve access to life-saving treatments for addressing other crucial health challenges.

McBee, Moore & Vanik IP: Intellectual Property Law Firm Celebrates Six Years

Published on : January 14, 2022 Published by : BioBuzz Media

McBee, Moore & Vanik IP, LLC began in 2016 when partners Susan McBee, C.G. Moore, David Vanik and 12 employees came together to form a new patent law firm with improved client service as the ultimate goal. This year, the firm is celebrating six years together.

TEDCO’s Maryland Venture Fund Invests $500K in Maryland Technology Start-up

Published on : January 12, 2022 Published by : BioBuzz Media

TEDCO’s Maryland Venture Fund Invests $500K in Maryland Technology Start-up Transformania is a Software as a Service (SaaS) with a data quality solution for Customer Relationship Management (CRM) software COLUMBIA, [….]

Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax’ COVID-19 Vaccine in South Africa

Published on : January 10, 2022January 10, 2022 Published by : BioBuzz Media

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume, today announced a regulatory submission to the South African Health Products Regulatory Agency (SAHPRA) for emergency use authorization (EUA) of Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. If authorized, the vaccine (known as NVX-CoV2373) will be manufactured by and commercialized by SII in South Africa under the brand name Covovax™.

Infectious Disease Focused Zalgen Labs Opens New HQ in Frederick, Eyes Clinical Trial for Lassa Fever Therapeutic

Published on : January 10, 2022January 10, 2022 Published by : Alex Keown

Zalgen Labs, which until late December been housed at the Germantown Innovation Center for the past eight years, is focused on developing diagnostics and therapeutics for infectious emerging viral threats that have become endemic in the far corners of the world, including diseases such as Lassa fever, Ebola and other hemorrhagic diseases.

Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn’s Disease Patients and Presents Additional Program Updates at 2022 Investor Event

Published on : January 7, 2022January 7, 2022 Published by : BioBuzz Media

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases, today provides a comprehensive update on the Company’s growth opportunities and mid-stage development portfolio.

REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy

Published on : January 7, 2022January 7, 2022 Published by : BioBuzz Media

REGENXBIO Inc. (Nasdaq: RGNX) today announced the clearance of its Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA) to evaluate RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy (Duchenne) in a first-in-human clinical trial. RGX-202 is designed to deliver a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal (CT) domain found in naturally occurring dystrophin. RGX-202 uses REGENXBIO’s proprietary NAV® AAV8 vector. REGENXBIO plans to initiate the trial in the first half of 2022.

POMSnet Falcon Dives Into Pharma and Biotech GMP Facilities Across the Globe

Published on : January 4, 2022January 4, 2022 Published by : BioBuzz Media

POMS Corporation releases POMSnet Falcon 2021.2 MES Dashboard and Analytics. POMSnet Falcon is perched to become the GMP facility standard for dashboards, reports, & analytics. Customers are flocking to install the data warehouse to aggregate batch record data across multiple geographies and provide a single point of access. POMS’s Software R&D team worked day and night for months to completely overhaul the outdated industry-standard PDF electronic batch record flat file. This tireless work has resulted in a data warehouse enabling pharma, biotech, and cell & gene therapy manufacturers to instantly access global batch record data and release products in real-time faster than any other product on the market.

This Charlottesville Company is Changing the Game in Wound Care

Published on : January 4, 2022January 4, 2022 Published by : Sarah Ellinwood

Molecular Biologicals, located in the blossoming biotech hub of Charlottesville, VA, is working to change the game in chronic wound care through its unique and proprietary keratin manufacturing platform.

You’ve likely heard of keratin before in some aspect – this protein is an essential part of our hair, skin, and nails, and is found as an ingredient in many haircare products. While keratin is touted for its ability to strengthen hair and tame frizz, make no mistake – the keratin that Molecular Biologicals is manufacturing is much different than what you’d find in the beauty aisle at your local drugstore.

Women In Bio Diversifies More Than 100 Life Science Boardrooms

Published on : December 30, 2021December 30, 2021 Published by : BioBuzz Media

Executive Women In Bio (EWIB), a Women In Bio (WIB) initiative, celebrates a milestone year in 2021 with the 100th Boardroom Ready Alumnae appointment to a corporate board in the life science industry. This year alone, more than 40 appointments took place, totaling 112 placements since the program’s inception. Boardroom Ready is an award-winning executive development platform designed to fuel women’s participation on corporate boards.